By: Daniel Gilbert
The personalised cancer drug is based on the same technology as the leading Covid shots.


Reporter Covering The Business Of Medicine
Daniel Gilbert is a Reporter Covering The Business Of Medicine at The Washington Post. He specializes in topics such as aging and longevity, diet and nutrition, gene therapy, immunotherapy, and pharmaceutical manufacturing, while also addressing themes related to family and relationships, particularly in the context of wellness programs and remote healthcare. His work has been featured in numerous publications, including the Anchorage Daily News, The Seattle Times, and The Boston Globe.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)


Not enough data
Daniel Gilbert's coverage revolves around the healthcare and pharmaceutical industries, with a focus on FDA announcements, legal policy regulation, and investment analysis. He frequently cites data to support his reporting.
For effective outreach to Daniel, consider providing insights into FDA approvals or rejections of new drugs, in-depth analyses of pharmaceutical companies' financial performance or strategic moves, and perspectives on the impact of regulatory changes on the healthcare industry. Expert commentary from professionals deeply involved in drug development processes or those with regulatory expertise would likely be well-received.
Given that Daniel appears to have a United States focus but does not explicitly limit himself geographically, pitches should take into account their relevance within the US market while also being mindful that international developments may also be relevant if they have implications for US-based companies or regulations.
This information evolves through artificial intelligence and human feedback. Improve this profile .